For instance, volagidemab (REMD-477), a monoclonal antibody targeting GCGR, has been shown to reduce insulin requirements and lower mean daily glucose by approximately 27 mg/dL over 24 hours in individuals with type 1 diabetes, without increasing the risk of hypoglycemia (58, 59). Here, GCGR is linked to type 1 diabetes mellitus.